Previous 10 | Next 10 |
LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Garo Armen, Chairm...
Image source: The Motley Fool. Agenus inc (NASDAQ: AGEN) Q3 2021 Earnings Call Nov 12, 2021 , 10:30 p.m. ET Operator Continue reading For further details see: Agenus inc (AGEN) Q3 2021 Earnings Call Transcript
Seventeen objective responses reported across nine cancers Evidence of monotherapy activity, with four cases of confirmed objective response Objective responses noted in treatment refractory, poorly immunogenic tumors including microsatellite stable (MSS) colorectal cancer, ovar...
A rather up-and-down stock even in the up-and-down world of biotech, Agenus (NASDAQ: AGEN) was seeing a bit of a peak on Tuesday. In mid-afternoon trading, the company's shares were up by 7.5% on the back of an encouraging earnings report. That morning, Agenus published its Q3 r...
Agenus Inc. (AGEN) Q3 2021 Earnings Conference Call November 9, 2021 08:30 ET Company Participants Divya Vasudevan - Investor Relations Garo Armen - Chairman and Chief Executive Officer Jennifer Buell - Chief Executive Officer, MiNK Therapeutics Steven O’Day - Chief Medical Officer Chr...
Agenus had its accelerated approval pathway for balstilimab blocked under suspicious circumstances. However, this may actually be a blessing because balstilimab monotherapy wasn't much of a market. Still, the FDA's action is not good. For further details see: Agenus: The...
Shares of Agenus (NASDAQ:AGEN) are up ~8% in premarket trading after the company's Q3 2021 earnings beat expectations due to a major increase in revenue. The revenue surge was due to upfront license fees received, milestones earned, and collaboration agreements. Revenue increased to...
Agenus (NASDAQ:AGEN): Q3 GAAP EPS of $0.72 beats by $0.26. Revenue of $252.94M (+1605.6% Y/Y) beats by $85.34M. Press Release Ended the third quarter of 2021 with a cash and short-term investment balance of $262M as compared to $100M at December 31, 2020. For further details see: Agenus...
Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and balstilim...
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Da...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...